{
    "medicine_id": "5a485cd99a8c0eac4c85a9aeaf4f24135821d10f",
    "platform_id": "DB06784",
    "metadata": {
        "name": "Gallium 2 0 mCi 1mL Injection",
        "composition": "2 0 mCi 1mL Gallium citrate Ga 67",
        "clinical_particulars": {
            "therapeutic_indications": "Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin s disease lymphoma and bronchogenic carcinoma Positive gallium Ga 67 uptake in the absence of prior symptoms warrants follow up as an indication of a potential disease state Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "It has been reported in the scientific literature that following intravenous injection the highest tissue concentration of gallium Ga 67 other than tumors and sites of infection is the renal cortex After the first day the maximum concentration shifts to bone and lymph nodes and after the first week to liver and spleen Gallium Ga 67 is excreted relatively slowly from the body The average whole body retention is 65 percent after seven days with 26 percent having been excreted in the urine and 9 percent in the stools",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}